Versuchen GOLD - Frei
5G's Healthcare Implications To Watch For
BioSpectrum Asia
|BioSpectrum Asia August 2021
From remote diagnosis, remote surgery, real-time monitoring to expanded telehealth etc. 5G represents a host of opportunities for healthcare. Let’s look at the possibilities of this technology for healthcare and how it can help bring a paradigm shift in the sector.
Fifth-generation (5G) has gained much importance, development and investment in recent years. This technology has the potential to transform all the components of healthcare, which is especially important as the COVID-19 pandemic has put unparalleled stress on healthcare systems around the world.
Network providers and healthcare institutions are figuring out how best to incorporate this technology into the ecosystem. A new private 5G network from AT&T is helping to revolutionise the way patients and researchers connect at the Lawrence J. Ellison Institute for Transformative Medicine of USC, USA. The on-site 5G network is providing ultra-fast connectivity for patient-centred cancer research, treatment, and wellness education. The Ellison Institute is among the first medical facilities in the USA using 5G to help advance cancer research.
South Korea’s KT Corporation and the Samsung Medical Center (SMC) are working to build a smart hospital. They have jointly developed an innovative, 5G-powered medical service as an initial step to establishing a 5G smart hospital.
Sharing his thoughts, Joe Drygas, AT&T VP of Healthcare Industry Solutions, USA said, “5G has the potential to offer massive connection power, fast speeds and low latency that can help transform how healthcare is delivered. Think remote robotic surgery and quick downloads and transference of massive data files of medical imagery. 5G not only has the capacity to impact the Internet of Medical Things, but it also will help enable medical innovations using augmented reality, virtual reality, artificial intelligence, remote medical learning, remote patient monitoring, and more. Healthcare providers will be able to build an entire ecosystem that creates highly responsive, effective, patient-centric experiences”.
Upgraded Telehealth
Diese Geschichte stammt aus der BioSpectrum Asia August 2021-Ausgabe von BioSpectrum Asia.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON BioSpectrum Asia
BioSpectrum Asia
India–EU FTA Paves Way for Expanded Healthcare Trade
On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India
In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Women's Health Surge in APAC
The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.
6 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer
Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Daiichi Sankyo names Dr John Tsai as Global Head of R&D
Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"
King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
SEOUL'S RISKY DRUG PRICING RESET
Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.
2 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules
Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9
US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
China revises drug administration regulations to spur innovation
China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.
1 min
BioSpectrum Asia March 2026
Translate
Change font size

